Cancer Chemotherapy and Pharmacology

, Volume 65, Issue 1, pp 27–32

Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck

  • Byoung Chul Cho
  • Ki Chang Keum
  • Sang Joon Shin
  • Hye Jin Choi
  • Young Joo Lee
  • Se Hun Kim
  • Eun Chang Choi
  • Joo Hang Kim
Original Article

DOI: 10.1007/s00280-009-0999-4

Cite this article as:
Cho, B.C., Keum, K.C., Shin, S.J. et al. Cancer Chemother Pharmacol (2009) 65: 27. doi:10.1007/s00280-009-0999-4

Abstract

Background

The objective of the study was to investigate the efficacy and tolerability of weekly docetaxel in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Methods

Patients fulfilling the following criteria were enrolled: histologically confirmed SCCHN; documented progressive disease (PD) after platinum-based treatment; Eastern Cooperative Oncology Group (ECOG) 0–2; measurable disease; not candidates for local therapy. Docetaxel (35 mg/m2) was administered for 3 weeks, every 4 weeks for a maximum of 6 cycles.

Results

A total of 23 patients were treated. All patients were assessable for toxicity and response. The overall response rate was 13.0% (3/23) and disease control rate was 34.7% (8/23). Median progression-free and overall survival (OS) was 9 (95% CI, 7.6–10.4 weeks) and 29 weeks (95% CI, 10.8–47.1 weeks), respectively. Most common hematological toxicities were grade 1–2 anemia (6/23, 26.1%) and nonhematological toxicities were mild and manageable. There was no treatment-related death.

Conclusion

Weekly docetaxel regimen had good clinical activity with an acceptable toxicity in patients with platinum-refractory SCCHN.

Keywords

Docetaxel Head and neck Squamous cell carcinoma Chemotherapy Platinum-refractory 

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Byoung Chul Cho
    • 1
  • Ki Chang Keum
    • 2
  • Sang Joon Shin
    • 1
  • Hye Jin Choi
    • 1
  • Young Joo Lee
    • 1
  • Se Hun Kim
    • 3
  • Eun Chang Choi
    • 3
  • Joo Hang Kim
    • 1
  1. 1.Yonsei Cancer Center, Division of Medical OncologyYonsei University College of MedicineSeoulKorea
  2. 2.Department of Radiation OncologyYonsei University College of MedicineSeoulKorea
  3. 3.Department of OtorhinolaryngologyYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations